Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 31, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
ESSENCE Phase 3 trial results demonstrating statistically significant ...
Nov 20, 2024 · The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed improvements in liver enzymes, including ...
STORM Therapeutics Presents New Clinical Data on its First-in …
Nov 11, 2024 · STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types. Gene expression data shows upregulation of innate immunity pathways
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease …
Nov 20, 2024 · Highlights: Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon’s lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~50% and ~55% respectively, in M337V Motor Neurons in response to a …
Seismic Therapeutic Presents New Preclinical Data for S-4321, a …
Nov 18, 2024 · Novel dual-cell bidirectional antibody engages two independent inhibitory receptors on multiple cell types in a single molecule. S-4321 is a low affinity PD-1 agonist with selective and functional FcγRIIb binding, without cell depleting activity. New preclinical data support differentiated profile, demonstrate induction of regulatory T cells and activity in a murine model of graft versus host ...
Capricor Therapeutics Completes Submission of Biologics License ...
Jan 2, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Capstan Therapeutics Presents Preclinical Data on Lead In Vivo …
Nov 18, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
DATROWAY® Approved in Japan as the First TROP-2 Directed …
Dec 27, 2024 · First global approval based on TROPION-Breast01 where DATROWAY significantly reduced the risk of disease progression or death by 37% versus chemotherapy
Wave Life Sciences Announces Submission of First Clinical Trial ...
Dec 23, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
REGENXBIO Presents Positive Data from the Phase II Study of …
Oct 21, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …